Group 1: Federal Reserve Interest Rate Decisions - There is increasing divergence within the Federal Reserve regarding the potential for interest rate cuts in December, with some officials suggesting further easing is possible while others see no need for a cut [6][7]. - Market expectations for a December rate cut fluctuated significantly, initially exceeding 90% but later dropping to around 30% due to data availability issues from the government shutdown [7]. - Following dovish comments from New York Fed President Williams, the probability of a 25 basis point cut rose to over 70%, but this was tempered by comments from Boston Fed President Collins [6][7]. Group 2: National Economic Performance - The National Bureau of Statistics reported that China's economy continued to show steady progress in October, with stable production and demand, and overall stability in employment and prices [8]. - Key indicators of economic performance include a 4.9% year-on-year increase in industrial output, with significant growth in advanced manufacturing and modern services [8]. - Emerging industries are becoming increasingly significant, with high-tech investments experiencing explosive growth, particularly in robotics and AI, contributing to high-quality economic development [8]. Group 3: Pension System Developments - The Ministry of Finance and the People's Bank of China announced that electronic savings bonds will be included in personal pension products starting June 2026, enhancing investment options for pension investors [10]. - This inclusion aims to fill the gap for low-risk, moderate-return products in the pension system, thereby improving the attractiveness and coverage of personal pension schemes [10]. Group 4: H-share Audit Business Expansion - The Ministry of Finance and the China Securities Regulatory Commission have initiated the expansion of the list of accounting firms eligible for H-share audits, adding two more firms to the existing list [11]. - This expansion is the first since December 2010 and aims to enhance the quality and international competitiveness of accounting services for companies seeking to list in Hong Kong [11]. Group 5: Sovereign Bond Issuance - The Chinese Ministry of Finance successfully issued €4 billion in sovereign bonds in Luxembourg, with a 4-year bond at a 2.401% interest rate and a 7-year bond at 2.702% [12]. - The issuance attracted a diverse range of global investors, indicating strong international confidence in China's economic resilience [12]. Group 6: U.S. Employment Data - In September, the U.S. non-farm payrolls increased by 119,000, significantly surpassing market expectations, while the unemployment rate rose to 4.4%, the highest since October 2021 [13]. - Job growth was primarily driven by the education and healthcare sectors, while cyclical industries like manufacturing and transportation showed weakness, indicating an unstable growth foundation [13].

证券研究报告 2025 年 11 月 24 日 湘财证券研究所 宏观研究 宏观研究深度报告 全球经济慢复苏，"十五五"引领新方向 ——宏观经济展望 相关研究： | 1. | 《经济磨底，政策加码》 | | | --- | --- | --- | | | 2023.10.18 | | | 2. | 《千磨万击还坚劲》 | | | | 2024.03.25 | | | 3. | 《东隅已逝，桑榆非晚》 | | | | 2024.06.24 | | | 4. | 《行到水穷处，坐看云起 | | | 时》 | | 2024.12.23 | 分析师：何超 证书编号：S0500521070002 Tel：021-50295325 Email： hechao@xcsc.com 地址：上海市浦东新区银城路88 号 中国人寿金融中心10楼 核心要点： ❑ 海外宏观：全球经济身处复苏周期 10 月 14 日，国际货币基金组织（IMF）发布最新一期《世界经济展望报 告》，小幅上调今年世界经济增长预期。报告将阿联酋今年经济增长预 期上调至 4.8%，高于其今年 4 月发布的预测。报告显示，中东和中亚地 区的经济增长将从 2024 年 ...

11月24日，华熙生物盘中上涨2.03%，截至13:15，报49.86元/股，成交6169.62万元，换手率0.26%，总 市值240.16亿元。 资金流向方面，主力资金净流出106.80万元，大单买入810.65万元，占比13.14%，卖出917.46万元，占 比14.87%。 截至10月31日，华熙生物股东户数3.06万，较上期增加0.86%；人均流通股15749股，较上期减少 0.85%。2025年1月-9月，华熙生物实现营业收入31.63亿元，同比减少18.36%；归母净利润2.52亿元，同 比减少30.29%。 分红方面，华熙生物A股上市后累计派现11.38亿元。近三年，累计派现5.28亿元。 机构持仓方面，截止2025年9月30日，华熙生物十大流通股东中，易方达上证科创板50ETF（588080） 位居第三大流通股东，持股696.42万股，相比上期减少101.36万股。华夏上证科创板50成份ETF （588000）位居第四大流通股东，持股681.95万股，相比上期减少382.34万股。华宝中证医疗ETF （512170）位居第七大流通股东，持股537.40万股，相比上期减少105.90万股。南方中 ...

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key emerging industry in China's economic transformation, highlighting its potential for sustainable development and economic benefits [1][3]. Economic Benefits - Biomanufacturing can convert waste into valuable resources and enhance cost efficiency. A newly developed enzymatic technology can convert 100% of nine types of crop straw into various industrial raw materials, reducing the cost of produced pulp by 30% to 40% compared to traditional chemical methods [2]. - The total scale of China's biomanufacturing industry is approaching 1 trillion yuan, with fermentation capacity accounting for over 70% of the global market. By 2030, industries currently contributing one-third of global GDP are expected to be reshaped by synthetic biology applications [2]. Sustainable Development - Biomanufacturing has significant low-carbon attributes, making it a crucial pathway to achieve carbon neutrality goals. Biobased products in the chemical sector can reduce emissions by 50% to 70% compared to petrochemical routes. A 30% substitution rate in the chemical and materials sectors could lead to a cumulative reduction of over 1.5 billion tons of CO2 by 2030 [3]. - Technologies in biomanufacturing can even enable "negative carbon" outcomes, as demonstrated by Shougang Longze, which utilizes steel industry waste gases to produce feed protein and fuel ethanol [3]. Policy Support and Development - The "14th Five-Year Plan" has identified biomanufacturing as a key development direction, with previous policies dating back to 2012 emphasizing the establishment of a biomanufacturing technology system [3]. - Recent initiatives by the Ministry of Industry and Information Technology and the National Development and Reform Commission aim to cultivate biomanufacturing pilot platforms and promote the integration of biotechnological industries [4]. - The collaborative efforts of government, industry, academia, and research will accelerate the commercialization of biomanufacturing innovations, creating new employment and entrepreneurial opportunities [4].

人工合成淀粉样品 可降解塑料餐具样品 微生物蛋白样品 利用人工途径从二氧化碳合成淀粉示意图。 二氧化碳如同覆盖在地球表面的"保温被"，适量存在能将地球表面平均温度维持在15摄氏度左右，使生 命繁衍成为可能。然而，工业革命以来，人类活动加剧，这床"被子"正在变得越来越厚。化石燃料燃 烧、土地利用变化等导致大气中温室气体浓度持续攀升，全球气温不断升高，随之而来的是冰川加速消 融、海平面上升、极端天气事件频发等一系列连锁反应。 面对这一严峻挑战，国际社会对碳中和愈加重视。减少排放是应对策略的一个方面。另一方面，如何将 二氧化碳转化为有用的资源，变被动减排为主动利用？这是可持续发展的思路。 中国科学院天津工业生物技术研究所人工合成淀粉研究中 心实验室。 以上图片均为中国科学院天津工业生物技术研究所提供 网友：我最近看到新闻，研究人员在尝试直接捕集海水中的二氧化碳，并合成为可生物降解的塑料。这 是不是属于"生物制造"的范畴？二氧化碳还能转化成什么？ 编辑：没错，你提到的正是当前科技前沿热点——二氧化碳不仅是温室气体，更是潜在的"碳资源"。 "十五五"规划建议提出，"完善新型举国体制，采取超常规措施，全链条推动集成电路、 ...

Core Viewpoint - The company, as the first IVD listed enterprise on the Sci-Tech Innovation Board, is transitioning from in vitro diagnostics to biopharmaceuticals, aligning with national biomanufacturing strategies and focusing on long-term growth in the biopharmaceutical sector [1][2] Group 1: Industry Trends and Strategic Positioning - Biomanufacturing is recognized as a strategic emerging industry for the next decade, with biopharmaceuticals being a key battleground due to high technical barriers [2] - The company's expansion from in vitro diagnostics to biopharmaceuticals is seen as a natural extension of its core biotechnological competencies, emphasizing the interconnectedness of diagnostic and therapeutic technologies [2] - The company has made significant investments in basic research, publishing multiple papers in top journals and establishing a solid R&D framework [2] Group 2: Innovation and Product Development - The company adheres to the "uniqueness and firstness" principle in its innovation pipeline, focusing on early screening for liver cancer and developing cutting-edge technologies in the field [4][5] - The company’s liver cancer early screening products are widely used in high-risk populations and have been included in expert consensus, contributing to early detection and treatment [4] - The company is also developing the world's first antibody drug for myocardial infarction, which has completed Phase I clinical trials and is preparing for Phase II [5] Group 3: Global Market Expansion - The company has initiated overseas expansion since 2019, achieving over 600 foreign certifications and establishing a presence in Southeast Asia, South Asia, the Middle East, and Latin America [6] - The company aims to provide high-quality, cost-effective medical products to developing countries, enhancing global health equity [6] - The company plans to increase its efforts in overseas market development, leveraging its strong technical capabilities and certification reserves [6] Group 4: Financial Commitment to R&D - The company's R&D investment as a percentage of revenue has been significant, with 24.29% in 2023, 22.18% in 2024, and 23.45% in the first half of 2025 [8]

Core Insights - The report indicates that China's high-end manufacturing sector has experienced significant growth over the past five years, with both the number of companies and asset scale increasing at a rate higher than the overall A-share market [1][2]. Group 1: Company Growth and Financial Performance - The number of high-end manufacturing companies increased from 1,661 in 2020 to 2,503 in 2024, with a compound annual growth rate (CAGR) of 10.80%, surpassing the overall A-share growth rate [1]. - By the end of 2024, the total market capitalization of this sector reached 32.47 trillion yuan, and total assets exceeded 27 trillion yuan, demonstrating strong resilience and a high-quality transformation [1]. - The total assets of high-end manufacturing companies grew at a CAGR of 13.98%, compared to 9.40% for the A-share market, while operating revenue increased from 9.36 trillion yuan in 2020 to 15.41 trillion yuan in 2024, with a CAGR of 13.27% [1]. - Net profit also showed a CAGR of 12.28%, indicating sustained profitability and growth potential [1]. Group 2: Economic and Social Contributions - In 2024, high-end manufacturing companies contributed 253.90 billion yuan in taxes, with a CAGR of 10.85%, and employed 10.35 million people, reflecting a CAGR of 9.00% [2]. - The sector has become a significant force in stabilizing employment and promoting innovation [2]. Group 3: Research and Development - R&D expenditure as a percentage of revenue increased from 5.06% in 2020 to 6.06% in 2024, with total R&D spending reaching 934.12 billion yuan in 2024, reflecting a CAGR of 18.51% [2]. - The number of R&D personnel rose from 1.17 million to 1.84 million, with a CAGR of 12.07%, driving technological advancement and industrial upgrades [2]. Group 4: International Expansion - From 2020 to 2024, overseas revenue for high-end manufacturing companies grew from 2.09 trillion yuan to 4.31 trillion yuan, with a CAGR of 19.81%, significantly outpacing the overall A-share overseas revenue growth [2]. - The share of overseas revenue in total A-share overseas income increased from 32.53% to 41.96%, indicating the sector's growing role in the international market [2]. Group 5: Market Management and Investor Returns - In 2024, total dividends paid by high-end manufacturing companies reached 362.95 billion yuan, an increase of 60.3 billion yuan year-on-year, with a dividend payout ratio of 52.59% [3]. - Share buybacks totaled 83.93 billion yuan, with sectors like semiconductors, communication equipment, and electronics leading in market value growth, reflecting corporate confidence in future development [3]. Group 6: Future Outlook - The report emphasizes that during the "14th Five-Year Plan" period, the high-end manufacturing sector transitioned from "catching up" to "keeping pace" and even "leading" [3]. - Looking ahead to the "15th Five-Year Plan," the report calls for a focus on new productive forces, targeting emerging fields such as low-altitude economy, quantum technology, and biomanufacturing, while also addressing key areas like integrated circuits and high-end medical equipment [3].

11月20日，东富龙盘中下跌2.01%，截至09:52，报16.55元/股，成交6441.71万元，换手率0.68%，总市 值126.74亿元。 分红方面，东富龙A股上市后累计派现17.82亿元。近三年，累计派现5.12亿元。 资金流向方面，主力资金净流出884.64万元，特大单买入0.00元，占比0.00%，卖出112.90万元，占比 1.75%；大单买入589.15万元，占比9.15%，卖出1360.89万元，占比21.13%。 东富龙今年以来股价涨25.62%，近5个交易日跌2.76%，近20日涨11.75%，近60日涨9.53%。 资料显示，东富龙科技集团股份有限公司位于上海市闵行区都会路1509号，成立日期1993年12月25日， 上市日期2011年2月1日，公司主营业务涉及医用冻干机及冻干系统的研发、设计、生产、销售和服务。 主营业务收入构成为：制剂事业部44.92%，生物工艺事业部29.83%，工程事业部9.19%，食品事业部 9.16%，售后服务与配件6.81%，其他(补充)0.09%。 东富龙所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：互联医疗、基因测序、生 物制造、合成 ...

Group 1 - The core viewpoint is that the Hong Kong stock market is expected to benefit from internal "14th Five-Year Plan" catalysts and external economic stimulus measures, leading to a recovery in performance and valuation by 2026 [1][2] - Emerging industries in Hong Kong stocks, as per the "14th Five-Year Plan," include solid-state batteries, brain-computer interfaces, biomanufacturing, quantum technology, and controllable nuclear fusion [1] - Bloomberg consensus forecasts indicate that Hong Kong stock performance will bottom out in 2025, with expected revenue and profit growth rates of 3.6% and 3.5% respectively, and a significant increase to 5.5% and 9.2% in 2026 [1] Group 2 - The liquidity environment in China has shown a notable "wealth effect," with a trend of residents reallocating deposits, which is expected to continue [1] - There is a low allocation of mainland investors in Hong Kong stocks, suggesting that southbound capital will continue to increase its allocation, particularly through ETF channels [1] - The Hong Kong market is poised to benefit from the outflow of liquidity from domestic and international markets, along with the ongoing narrative surrounding AI [1] Group 3 - The Hong Kong stock market is anticipated to experience a second round of valuation recovery and further performance resurgence in 2026, driven by a rebound in fundamentals and significant valuation discounts [2] - Recommended long-term investment directions include: 1) Technology sector, particularly AI-related segments and consumer electronics; 2) Healthcare sector, especially biotechnology; 3) Resource commodities benefiting from rising overseas inflation expectations and de-dollarization; 4) Essential consumer goods expected to see valuation recovery as the domestic economy improves; 5) Paper and aviation sectors benefiting from RMB appreciation [2]

日前公布的《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》中，首次将生物制造与 量子科技、具身智能等并列为六大未来产业。近十年来，中国从过去以仿制药为主的产业结构，逐步转 向以创新药为核心的研发模式，引起全球市场前所未有的关注。 华大集团CEO尹烨长期活跃在生物医学科普领域，在接受《环球时报》记者专访时，他用通俗的语言从 生物制造本身讲起，延伸到全球生物医药领域的竞争，在他看来万物皆是"生物制造"。 而面对发达国家领先的技术优势、多变的地缘政治等诸多困难，尹烨表示要相信"中国在1到100的本事 全球最强，从0到1的原始创新正在快速赶上，而且下一代人会更优秀"。 生物制造产业前景不可估量 环球时报：今年的《政府工作报告》首次将生物制造作为未来产业正式提出。您怎么理解生物制造在中 国产业板块中的地位？ 尹烨：生物制造领域中有很多"奇迹"在发生。最近在上海证券交易所科创板上市的一家生物科技企业禾 元生物，核心技术是"稻米造血"。据介绍，一棵水稻就可以产出人类血浆中的重要成分"人血清白蛋 白"，有望解决我国人血清白蛋白长期依赖进口的局面。听起来不可思议，但这就是生物制造的魅力。 中美站在同一起跑线上 环球 ...